Our story
Jotbody (HK) Limited, established in 2020, is a cutting-edge biotechnology company excelling in nanobody research and extracellular vesicles (EVs). Our commitment to advancing global research and development is upheld by a team of seasoned scientists and dedicated board members.
Specializing in nanobody discovery technology, we boast a rich background in customizing camelid VHH and shark vNAR. Providing a full spectrum of services in nanobody research and development, we cater to diverse needs—from antigen design and preparation to nanobody humanization and affinity maturation, along with protein expression and coupling modification services.
Our mission revolves around the development and application of nanobodies. With an international first-class team deeply immersed in biopharmaceuticals and life science tools, we leverage an advanced nanobody discovery and engineering technology platform to deliver tailored nanobody development services and high-performance research reagents to customers across over 20 countries and regions. Notably, our efforts were acknowledged by Forbes Asia in their “100 Companies to Watch in 2023” list.
Moreover, since 2014, we have been actively engaged in EV research, collaborating closely with industry and academic partners. Noteworthy is our partnership with Dr. Minh Le from the National University of Singapore, an expert in utilizing red blood cell-derived EVs for therapeutic applications. This collaboration has enabled us to excel in EV modification for therapeutic applications, demonstrating efficacy across various disease models such as cancer, neurodegenerative disorders, cardiovascular diseases, and inflammatory conditions.
Within the realm of EVs, we offer a comprehensive suite of services tailored to meet the evolving needs of researchers worldwide. From isolation and purification to characterization, omics analysis, functionalization, and CDMO solutions, we stand as a reliable partner for researchers delving into the complexities of intercellular communication and harnessing the therapeutic benefits of EVs.
At the core of our vision lies the goal of elevating life sciences through the precision of nanobodies and the incredible potential of extracellular vesicles. We are passionate about fostering collaboration, igniting innovation, and upholding the highest standards of quality in all our endeavors, driving significant progress in the fields of nanobody research and EVs.
Selected customer references
“It is truly a five-star experience regarding order handling, technical support, and product quality. After trying other vendors for nanobody generation, Jotbody is the one I will definitely recommend to my colleagues” – Bill Wong | VP Preclinical Development, InnoRNA
“I am writing to express my sincere appreciation for the quality of antibody service you provided. I really appreciate your efficient, gracious service, the level of detail, professionalism, and accountability you have demonstrated on my project, and the way you conduct business as a whole.” – Hua Zhang | VP and Chief Scientific Officer, SPH Biotherapeutics
“We achieved successful cell targeting using your nanobody-clicked EVs. Thanks for your continuous support – it has been great working with you” – Anna Cifuentes-Rius | Director Research & Innovation, Exopharm
“We are very satisfied with your reactivity and therefore the overall experience with Jotbody is globally positive” – Jakub Toczek, PhD | Université Grenoble Alpes, Inserm
Strategic partnerships
We are always on the lookout for innovative solutions that can address unmet needs. If you feel that your product aligns with our vision, we would be thrilled to explore the possibility of working together.
